FRESENIUS SE & CO. KGAA The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi's biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**.
With Idacio Fresenius Kabi expands the U.S. biosimilars portfolio focused on immunology and oncology. It is the company's second approved U.S. biosimilar launching from July 2023 in accordance with the patent settlement agreement with Abbvie.
* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 14 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 December 2022 08:25:01 UTC.
